Inovio Pharmaceuticals Inc. (INO) had a rough trading day for Thursday December 05 as
tumbled 5.67%, or a loss of $-0.14 per share, to close at $2.33. After opening the day at $2.46, shares of Inovio Pharmaceuticals Inc. traded as high as $2.49 and as
low as $2.31. Volume was 983,150 shares over 4,743 trades, against an average daily volume of n/a shares and a total float of 100.01 million.
As a result of the decline, Inovio Pharmaceuticals Inc. now has a market cap of $233.02 million. In the last
year, shares of Inovio Pharmaceuticals Inc. have traded between a range of $5.43 and $1.92, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
For a complete fundamental analysis of Inovio Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Inovio Pharmaceuticals Inc. is based out of Plymouth Meeting, PA and has some 281 employees. Its CEO is J. Joseph Kim.
Inovio Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an
industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an
objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives
a broad, unbiased look at the small-cap market as a whole.
To get more information on Inovio Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here:
INO’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer